Serodus ASA has begun its first Phase IIa study with SER100 in patients suffering from Isolated Systolic Hypertension (ISH). The first patient has been enrolled in the study; the company plans to enroll a total of 30 patients during the next few months. The company expects that the last patient will be dosed in the end of the 1Q14. Isolated Systolic Hypertension (ISH) is the leading hypertensive disease in elderly people. SER100 is a new compound with a first-in-class mode of action; the compan...